- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05146219
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
January 28, 2024 updated by: TYK Medicines, Inc
A Phase II, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain or Leptomeningeal Metastases
To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This is an open label, multi-center phase II study to evaluate the efficacy and safety in EGFR mutated NSCLC patients with brain or leptomeningeal metastases.
The patients will be assigned to the appropriate treatment cohorts based on the criteria.
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yuankai Shi, MD
- Phone Number: +86-10-87788293
- Email: syuankaipum@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients diagnosed with non-small cell lung cancer (NSCLC) by histology or cytology, and with brain and leptomeningeal metastases. For LM patients, the diagnosis of leptomeningeal metastasis requires detection of cancer cell or EGFR mutation in the CSF.
- Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites). A positive T790M mutation is required for patients who have progressed following prior 1/2 generation EGFR-TKI therapy.
- Stable brain/leptomeningeal metastases that do not require immediate or planned local treatment for it during the study period.
- Presence of intracranial and extracranial measurable lesions without local treatment at the same time.
- The ECOG score is 0-2 (including 0 and 2), and there is no deterioration 2 weeks before the study, and the expected survival is not less than 3 months.
Adequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
- Absolute neutrophil count ≥1.5×109/L and white blood cell count ≥3×109/L;
- Platelet count ≥100×109/L;
- Hemoglobin ≥90g/L;
- Serum creatinine ≤1.5× upper normal limit (ULN) and creatinine clearance ≥50 mL/min (calculated according to the Cockcroft and Gault formula);
- AST and ALT≤2.5×ULN if no confirmed liver metastasis; AST, ALT≤5×ULN if confirmed liver metastasis;
- Total bilirubin ≤1.5×ULN in the absence of proven liver metastasis; total bilirubin ≤3×ULN in patients with proven liver metastasis or Gilbert syndrome (hyperindirect bilirubinemia);
- International standardized ratio (INR) ≤1.5, and activated partial prothrombin time (APTT) ≤1.5×ULN.
- Male patients and female patients of reproductive age should take adequate contraceptive measures from signing informed consent to 3 months after the last study drug treatment; Women of childbearing age have negative pregnancy test results within 7 days of the first dose.
- Patients having recovered from all grade ≤ 1 toxicities related to previous anticancer therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy (where ≤2 is allowed) before first dose of study treatment.
- Patients can understand and voluntarily sign the informed consent form.
- Patient able to comply with study requirements.
Exclusion Criteria:
Any of the following treatment:
- Previous treatment with 3rd generation EGFR inhibitor (Osimertinib, Almonertinib, Furmonertinib, etc.);
- The time from the treatment of reversible EGFR-TKI (e.g., Gefitinib, Erlotinib, Icotinib) to the first administration of the drug in this study did not exceed 8 days or 5 half-lives (whichever is longer); the time from the treatment of irreversible EGFR-tkis (e.g., Afatinib, Dacomitinib, Neratinib, etc.) do not exceed 14 days or 5 half-lives (whichever is longer);
- Previous treatment with Systematic antitumor therapy, including standard chemotherapy, biotherapy and immunodrug therapy within 28 days before the first dose of the study drug, and traditional Chinese medicine antitumor therapy within 7 days before the first dose of the study drug.
- Receiving radiation to more than 30% of the bone marrow or with a wide field of radiation that had to be completed within 28 days of the first dose of study treatment; Radiotherapy with a limited field of radiation within 7 days of the first dose of study treatment or palliative radiation therapy for bone metastasis;
- Previous treatment with whole brain radiotherapy (WBRT). Patients who have previously received stereotactic radiotherapy (SRT) or other CNS local treatments (such as intrathecal chemotherapy) can be enrolled if the time from the completion of treatment to the initial study medication is more than 2 weeks;
- Uncontrollable pleural and abdominal effusion. For patients with pleural effusion, pleural effusion should be stabilized for 2 weeks prior to initial medication (diuretics, pleural effusion or pleural infusion are not allowed during this period);
- Major surgery within 4 weeks of the first dose of study treatment;
- Patients currently receiving (or at least within 14 days prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A4.
- Patients who are receiving and need to continue receiving medications during the study that are known to prolong the QTc interval or may cause tachycardia;
- Participants in other clinical trials (other than non-interventional clinical trials) within 28 days prior to the first administration of the investigational drug.
- Patients with leptomeningeal metastases (LM) who cannot be examined with enhanced MRI. Presence of leptomeningeal metastases only.
- Patients with CNS complications requiring emergency neurosurgical treatment (e.g. surgery, etc.). Patients with CNS symptoms should be controlled by glucocorticoids with an equivalent dose of more than 5mg dexamethasone 5 days prior to initial administration.
- Patients have spinal cord compression caused by tumor.
- Clinically severe gastrointestinal dysfunction may affect the ingestion, transport or absorption of the study drugs.
Cardiac function and disease are consistent with the following:
- Corrected QT interval(QTc)> 470 milliseconds from 3 electrocardiograms (ECGs);
- Any clinically important abnormalities in rhythm;
- Any factors that increase the risk of QTc prolongation;
- Left ventricular ejection fraction (LVEF) <50%.
- Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers.
- Previous history of interstitial lung disease(ILD)#drug-induced ILD or radiation pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases.
- Previous allogeneic bone marrow transplant.
- Pregnant or lactating women.
- Any other disease or medical condition that is unstable or may affect the safety or study compliance.
- Hypersensitivity to TY-9591 or similar compounds or excipients.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TY-9591 Tablets
TY-9591 Tablets 160mg/d
|
TY-9591 Tablets 160mg/d
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracranial Overall Response Rate (iORR)
Time Frame: 13 months.
|
iORR is defined as the proportion of patients with a best intracranial response of complete response (CR) or partial response (PR) during the study treatment
|
13 months.
|
Extracranial Overall Response Rate (eORR)
Time Frame: 13 months.
|
eORR is defined as the proportion of patients with a best extracranial response of complete response (CR) or partial response (PR) during the study treatment
|
13 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: 13 months.
|
ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) during the study treatment
|
13 months.
|
Disease Control Rate (DCR)
Time Frame: 13 months.
|
DCR is defined as the proportion of patients with a best overall response of complete response (CR) , partial response (PR) or Stable disease (SD) ≥6 weeks during the study treatment
|
13 months.
|
Duration of Response (DoR)
Time Frame: 13 months.
|
DoR is defined as the time from the date of first documented response (PR or CR) until the date of first documented disease progression or death due to any cause during the study treatment
|
13 months.
|
Median Progression Free Survival (PFS)
Time Frame: 13 months.
|
PFS is defined as time from date of first dose of study treatment until the date of first documented disease progression or death due to any cause
|
13 months.
|
Intracranial Median Progression Free Survival (iPFS)
Time Frame: 13 months.
|
iPFS is defined as time from date of first dose of study treatment until the date of first documented intracranial disease progression or death due to any cause
|
13 months.
|
Overall Survival (OS)
Time Frame: From the date of first dose until the date of death from any cause or loss to follow-up, whichever comes first, assessed up to 100 months
|
OS is defined as the time from the date of first dose of study treatment until death from any cause
|
From the date of first dose until the date of death from any cause or loss to follow-up, whichever comes first, assessed up to 100 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yuankai Shi, MD, Cancer Institute/Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 2, 2022
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
November 10, 2021
First Submitted That Met QC Criteria
November 23, 2021
First Posted (Actual)
December 6, 2021
Study Record Updates
Last Update Posted (Actual)
January 30, 2024
Last Update Submitted That Met QC Criteria
January 28, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Neoplastic Processes
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Meningeal Neoplasms
- Neoplasm Metastasis
- Brain Neoplasms
- Neoplasms, Second Primary
- Meningeal Carcinomatosis
Other Study ID Numbers
- TYKM1601201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Shanghai Henlius BiotechCompleted
-
The Netherlands Cancer InstituteEnrolling by invitation
-
Centre Oscar LambretUniversity Hospital, LilleTerminated
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdCompleted
-
Bio-Thera SolutionsCompleted
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
TYK Medicines, IncRecruiting
-
Radboud University Medical CenterPfizer; ImaginAb, Inc.; University Hospital TuebingenNot yet recruitingNSCLCGermany, Netherlands
-
Beta Pharma, Inc.Completed
Clinical Trials on TY-9591 Tablets
-
TYK Medicines, IncRecruitingNSCLC | EGFR Activating MutationChina
-
TYK Medicines, IncRecruiting
-
TYK Medicines, IncCompletedHealthy VolunteersChina
-
TYK Medicines, IncCompleted
-
TYK Medicines, IncRecruitingNSCLC | Brain Metastases | EGFR Activating MutationChina
-
TYK Medicines, IncRecruitingMetastatic Solid Tumor | Locally Advanced Solid TumorUnited States
-
TYK Medicines, IncRecruitingNeoplasms | Medullary Thyroid Cancer | RET-altered Non Small Cell Lung Cancer | RET-altered Papillary Thyroid CancerChina
-
TYK Medicines, IncRecruitingSolid Tumor, AdultChina
-
Henry Ford Health SystemCompleted
-
TYK Medicines, IncRecruiting